$COCP This is a great biotech play. Shares are cheap, volume has been building as buyers accumulate. Institutions have been loading, which is a good sign. Only 68m shares OS. This is ready to pop to higher levels upon any release of positive news. - The company has no debt and strong cash balance, so the risk of offerings or R/S is minimal. - Institutional buyers have been snatching up shares. - Several partnerships, including one with Merck. - Large pipeline: